Clinical trial Recruiting at 1 site Observational Ages 18 and up

Using MRI to study kidney disease and its complications

Official title: Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Patients With Kidney Disease

Run by University of Edinburgh · NCT06698614 · Data updated 2026-11-12

This study is testing if a special type of MRI can help find out more about kidney problems and their effects on heart health in people with acute kidney injury and chronic kidney disease.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment120 (estimated)
SponsorUniversity of Edinburgh
Academic / other
Locations1 site (Edinburgh)
StatusRecruiting
StartedNovember 7, 2024
Main results expectedNovember 7, 2029
Study endsNovember 7, 2029
Registry record updatedDecember 8, 2025
Trial IDNCT06698614 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults over 18 years old with a diagnosis of acute kidney injury or stable chronic kidney disease.

Probably not a fit

Patients who are pregnant or unable to provide informed consent will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the potential of manganese-enhanced magnetic resonance imaging (MEMRI) as a biomarker for acute kidney injury (AKI) and its associated cardiovascular and renal complications. The study will involve blood and urine tests, as well as cardiovascular analysis, to assess the relationship between kidney health and cardiovascular disease. Participants will include individuals diagnosed with AKI and chronic kidney disease (CKD), with the goal of identifying those at risk for further complications. The study will be conducted at NHS Lothian in Edinburgh.

Why it matters

Potential benefit: If successful, this study could provide a reliable biomarker for predicting cardiovascular disease in patients with kidney conditions.

How similar studies have gone: While the use of MEMRI is a novel approach, preliminary data suggest potential success in similar applications.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

All subjects to be entered must:

Be able to provide written informed consent after having received oral and written information about the study.

\>18 years of age Availability to complete study visits If female, be non-pregnant as evidenced by a negative pregnancy test or be post-menopausal or surgically sterile.

Additionally, cohort specific inclusion criteria are as follows:

Cohort 1; Acute kidney injury-

A diagnosis of AKI will be made based on the following criteria (based on the definition used in the Kidney Precision Medicine Project www.kpmp.org):

Previous (within 3 years) eGFR \>45 ml/min/1.73m2 OR no history of kidney disease if no blood results available AND Elevated creatinine \>1.5x previous result OR \>150 μmol/L if no previous value AND Increasing creatinine within 48 hours OR requirement for dialysis.

Cohort 2; Chronic kidney disease- Stable CKD for at least 6 months (monitored by eGFR), matched to AKI cohort at follow up based on renal function.

Cohort 3: Matched controls- Matched to AKI cohort participants at baseline for age, sex, cardiovascular disease risk and cardiovascular medication.

Cohort 4; Vasculitis- A new diagnosis of vasculitis or an existing diagnosis with relapsing disease, and kidney involvement.

Cohort 5; Kidney transplantation- Has kidney failure and has received a kidney transplant in the preceding 1 month.

Cohort 6: Kidney transplant rejection- Biopsy proven episode of transplant rejection.

Exclusion Criteria:

The following criteria apply to all patients:

1. Unable to give informed consent.
2. Have any contraindications to standard MRI safety criteria, including implanted devices.
3. Subjects under the age of 18 years old.
4. Pregnancy/positive pregnancy test.
5. Current breastfeeding.
6. Have a diagnosis of kidney disease due to polycystic kidney disease.
7. Patients in critical care or on surgical wards will be excluded.
8. Patients taking calcium channel antagonists or digoxin.

Additionally, cohort specific exclusion criteria are as follow:

Cohort 1- Excluded if they have a diagnosis of diabetes. Cohort 2- Excluded if receiving dialysis or those with a functional kidney transplant, multi-system disorders (e.g., systemic vasculitis), or any patients receiving immunosuppression.

Where it's running

  • NHS Lothian
    Edinburgh, United Kingdom
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.